New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Health-Related Quality of Life Outcomes in PARAGON-HF.
Health-Related Quality of Life Outcomes in PARAGON-HF. European journal of heart failure Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., Zile, M. R., Desai, A. S., Pfeffer, M. A., McMurray, J. J., Solomon, S. D., Lewis, E. F. 2022Abstract
AIMS: Heart failure (HF) is associated with poor health-related quality of life (HRQL). Patients with HF with preserved ejection fraction (HFpEF) have similar HRQL impairment as those with reduced ejection fraction. This study describes the impact of sacubitril/valsartan on HRQL in patients with HFpEF enrolled in the PARAGON-HF trial.METHODS AND RESULTS: Patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQol (EQ) at randomization, 4 months, 8 months, and annually thereafter. Changes in HRQL scores were evaluated using repeated measures models adjusted for treatment, baseline values and region. The pre-specified principal efficacy assessment was at 8 months at which time patients randomized to sacubitril/valsartan had borderline higher KCCQ-Clinical Summary score (CSS) with LSM adjusted difference of 1.0 (95% CI 0.0, 2.1); p=0.051. Including all visits up to 36 months, the LSM difference in KCCQ-CSS favored sacubitril/valsartan with average adjusted difference of 1.1 (95% CI 0.1, 2.0); p=0.034. Patients treated with sacubitril/valsartan had greater odds of clinically meaningful improvement (=5-point increase) in KCCQ-CSS (OR 1.31; 95% CI 1.06, 1.61) at 8 months. At 8 months, there was no significant difference in the EQ visual analogue scale between the treatment arms, but sacubitril/valsartan was associated with higher EQ-5D utility score (US-based) with LSM adjusted difference of 0.01 (95% CI 0.00, 0.02); p=0.019.CONCLUSION: Compared with valsartan, sacubitril/valsartan has a borderline benefit on KCCQ-CSS at 8 months in patients with HFpEF. This benefit became more significant when data from all visits up to 36 months were included. This modest overall benefit was also supported by greater odds of patients reporting a clinically meaningful improvement in HRQL with sacubitril/valsartan. This article is protected by copyright. All rights reserved.
View details for DOI 10.1002/ejhf.2738
View details for PubMedID 36394533